Ron Carozza, PharmD
Chief Executive Officer and Director, Clinical Operations

Prior to co-founding C3 Research in 2008, Ron held various positions in academic institutions, large pharma and biotechnology companies. He has over 25 years of clinical operations experience focused primarily on oncology, neurology, women’s health, hematology and clinical pharmacology studies. At C3 Ron is responsible for leading C3 Research’s business and clinical operations as well as growing its brand and geographic reach. Ron plays an instrumental role in designing and implementing a vision and strategic direction that has resulted in C3 Research emerging as a reputable and quality driven performance CRO. Ron has made significant contributions to nearly a hundred studies spanning a broad therapeutic range and phase of development and has played an integral role supporting numerous FDA approvals.

Gary Jones, MD
Chief Medical Officer and Director, Clinical Development

Gary co-founded C3 Research in 2008. Dr. Jones is a Board-Certified Pediatrician with a sub-specialty in hematology/oncology. He brings over 30 years of experience in the clinical development of therapeutics, supportive care measures and medical devices. His experience spans academic, real-world clinical and biotechnology environments including KOL/advisor communications, protocol development as well as creating and running early to late phase clinical trials with commercialization intent. His industry experience includes medical director positions at Berlex and Bayer as well as heading the development for clients for over a decade at C3 Research. To date, he has worked on over 125 clinical trials across a wide spectrum of clinical indications.


Lynn Shemanski, PhD
Director, Biometrics

Lynn has over 30 years of biostatistical experience in clinical trial design and analysis. She has been Director of Biometrics at drug companies and CROs, thereby bringing a unique understanding of both Sponsor and CRO outlooks. Dr. Shemanski’s biostatistical experience spans early to late phase clinical trials and has resulted in several successful new drug applications. Dr. Shemanski’s industry experience includes director positions at Zymogenetics (a subsidiary of Bristol Meyers Squibb) and Axio Research (a CRO subsidiary of Cytel). She has served as both Independent (reporting) and DSMB statistician on several clinical trials throughout her career. To date, she has worked on over 100 clinical trials across a wide spectrum of clinical indications.

George Merino
Vice President, Business Development

George joined C3 Research in 2017. He has over 20 years of transaction experience, of which over a decade has been devoted to the practice of business development and clinical operations within the clinical development industry. Since joining industry, he has held executive leadership responsibilities across early and late phase CRO providers. Since joining the C3 Research team, George has played an instrumental role in contributing to the growth of the company. He brings with him a unique vision that places the individual needs of every client, central to all the division’s business practices. His day-to-day contributions are grounded in a simple yet profound idea — good and proper business development lends itself to a strong foundation for dynamic and comprehensive solutions and a tailored approach to meeting biotech and pharmaceutical development challenges.

Katie Stevens
Director, Business Operations

Katie joined C3 Research in 2011. She brings a wealth of business and operational experience to the team. With over 15 years of operational experience, Katie has proven to be instrumental in building an environment where C3 employees love to work. She continues to manage the Business Operations department for this growing company in an ever-evolving industry with her expertise in financial planning, accounting, human resources, operations risk management, purchasing, and many other areas. Throughout her career, she has been instrumental in aligning the company infrastructure, developing business systems and plans, managing the complete employee life-cycle and building and administering C3’s benefit programs. Katie believes that it is important for a business to value its employees as well as its community and strives to make C3 an amazing place to work every day.